Immunovant Inc
IMVTHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:44 AM ET
36.50+0.79 (2.22%)
2026-11-11 16:44 CET
Market cap
7,376.01 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-508.96 USD m
Free cash flow, TTM
-395.01 USD m
EPS diluted, TTM
-2.55
P/E
-
Price
IMVT against its 20, 50 and 200-day averages2050200beatmiss
19.6% under the 52-week high of 45.42 on 19 Aug 2026. 52-week low 21.86 on 21 Nov 2025. Last 15 sessions, 32.8% high to low
Profile
IMVT52-week range, 62% of the way up
21.8645.42
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
| Index | RUT |
|---|---|
| Employees | 315 |
| IPO | Jun 21, 2019 |
| Beta | 0.91 |
| ATR, 14d | 1.52 |
| Rel volume | 0.43 |
| Short float | 21.87% |
| Insider own | 58.93% |
| Inst own | 52.67% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 7.55B |
| Enterprise Value | 6.83B |
| Income | -508.96M |
| Sales | 0.00M |
| Book/sh | 3.18 |
| Cash/sh | 3.49 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 315 |
| IPO | Jun 21, 2019 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 11.49 |
| P/C | 10.46 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 7.31 |
| Current Ratio | 7.31 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -2.55 |
|---|---|
| EPS next Y | -2.61 |
| EPS next Q | -0.62 |
| EPS this Y | 8.28% |
| EPS next Y | -2.64% |
| EPS next 5Y | 15.92% |
| EPS past 3/5Y | -17.37% -17.75% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 9.82% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 35.42% |
| Sales Q/Q | - |
| Earnings | Nov 09 BMO |
| EPS/Sales Surpr. | 36.23% - |
Ownership
| Insider Own | 58.93% |
|---|---|
| Insider Trans | -0.30% |
| Inst Own | 52.67% |
| Inst Trans | 0.75% |
| ROA | -75.74% |
| ROE | -86.51% |
| ROIC | -77.47% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | 22.64% |
| SMA50 | 11.24% |
| SMA200 | 13.15% |
| Trades | - |
Technical
| Shs Outstand | 206.79M |
|---|---|
| Shs Float | 84.83M |
| Short Float | 21.87% |
| Short Ratio | 12.88 |
| Short Interest | 18.55M |
| 52W High | 45.42 -19.63% |
| 52W Low | 21.86 66.98% |
| Volatility | 6.19% 4.35% |
| ATR (14) | 1.52 |
| RSI (14) | 69.42 |
| Beta | 0.91 |
| Rel Volume | 0.43 |
| Avg Volume | 1.44M |
| Volume | 142,538 |
Performance
| Perf Week | 22.08% |
|---|---|
| Perf Month | 27.14% |
| Perf Quarter | -12.72% |
| Perf Half Y | 24.79% |
| Perf YTD | 43.60% |
| Perf Year | 59.47% |
| Perf 3Y | 11.87% |
| Perf 5Y | 330.96% |
| Perf 10Y | - |
| Recom | 1.47 |
| Target Price | 48.06 |
| Prev Close | 35.71 |
| Price | 36.50 |
| Change % | 2.22% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Mar 20, 2026 | Initiated | BBernstein | Mkt Perform | $28 | -23.3% |
| Jan 06, 2026 | Upgrade | WWolfe Research | Peer Perform → Outperform | $50 | +37.0% |
| Oct 14, 2025 | Initiated | TTruist | Hold | $16 | -56.2% |
| Jul 10, 2025 | Resumed | GGoldman | Neutral | $18 | -50.7% |
| Mar 03, 2025 | Initiated | JJefferies | Hold | $20 | -45.2% |
| Jan 03, 2025 | Downgrade | WWolfe Research | Outperform → Peer Perform | ||
| Oct 10, 2024 | Resumed | RRaymond James | Outperform | $36 | -1.4% |
| Oct 09, 2024 | Reiterated | OOppenheimer | Outperform | $47 → $53 | +45.2% |
| Mar 28, 2024 | Initiated | OOppenheimer | Outperform | $50 | +37.0% |
| Mar 13, 2024 | Initiated | GGoldman | Buy | $50 | +37.0% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ARGX | Argen X SE ADR | 60.92B |
| VRDN | Viridian Therapeutics Inc | 3.49B |
| DNTH | Dianthus Therapeutics Inc | 4.99B |
| ROIV | Roivant Sciences Ltd | 29.90B |
| SYRE | Spyre Therapeutics Inc | 9.93B |
| VERA | Vera Therapeutics Inc | 2.17B |
| JNJ | Johnson & Johnson | 667.73B |
| KYTX | Kyverna Therapeutics Inc | 319.11M |
| CABA | Cabaletta Bio Inc | 297.69M |
| AMGN | AMGEN Inc | 249.75B |
Insider trading
latest 14 of 66| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Girao Tiago | Chief Financial Officer | Oct 28 '26 | Sale | 28.50 | 6,606 | 188,271 | 234,192 | Oct 30 04:37 PM |
| Stout Jay S | Chief Technology Officer | Oct 21 '26 | Sale | 28.94 | 2,595 | 75,099 | 198,937 | Oct 23 04:55 PM |
| Stout Jay S | Chief Technology Officer | Oct 07 '26 | Sale | 32.06 | 3,809 | 122,117 | 201,532 | Oct 09 05:05 PM |
| Van Tuyl Christopher | Chief Legal Officer | Oct 07 '26 | Sale | 32.06 | 1,327 | 42,544 | 175,218 | Oct 09 05:05 PM |
| Gloria Melanie | Chief Operating Officer | Oct 07 '26 | Sale | 32.06 | 2,241 | 71,846 | 217,060 | Oct 09 05:04 PM |
| Venker Eric | Chief Executive Officer | Oct 01 '26 | Option Exercise | 14.46 | 92,187 | 1,333,024 | 346,467 | Oct 05 07:42 PM |
| Venker Eric | Chief Executive Officer | Oct 02 '26 | Sale | 34.11 | 3,506 | 119,590 | 257,075 | Oct 05 07:42 PM |
| Van Tuyl Christopher | Chief Legal Officer | Sep 23 '26 | Sale | 36.36 | 2,846 | 103,481 | 176,545 | Sep 25 04:05 PM |
| Pande Atul | Director | Aug 28 '26 | Option Exercise | 8.43 | 1,500 | 12,645 | 118,231 | Aug 28 04:27 PM |
| Pande Atul | Director | Aug 28 '26 | Sale | 43.27 | 1,500 | 64,905 | 116,731 | Aug 28 04:27 PM |
| Gloria Melanie | Chief Operating Officer | Aug 20 '26 | Sale | 44.16 | 3,056 | 134,953 | 219,301 | Aug 21 04:03 PM |
| Pande Atul | Director | Jul 24 '26 | Option Exercise | 8.43 | 1,500 | 12,645 | 118,231 | Jul 24 05:59 PM |
| Pande Atul | Director | Jul 24 '26 | Sale | 39.80 | 1,500 | 59,700 | 116,731 | Jul 24 05:59 PM |
| Girao Tiago | Chief Financial Officer | Jul 23 '26 | Sale | 38.69 | 6,798 | 263,015 | 240,798 | Jul 24 05:57 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.50B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 79.59B |
| VBK | Vanguard Morningstar Small-Cap Growth ETF | AUM: 22.34B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.06B |
| IBB | iShares Biotechnology ETF | AUM: 11.36B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.75B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.25B |
News
latest 14 of 206- Immunovant surges on trial results, earnings beat (Investing.com) +15.13%
- Immunovant's Narrower Loss Matters Less Than An RA Win That Only The Higher Dose Delivered (Earnings Whispers)
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 (GlobeNewswire)
- Immunovant Heads Into Q3 With Flat Losses Expected And A 23% Slide To Explain (Earnings Whispers)
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire)
- Loading…
- IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits) -5.56%
- Lillys latest China drug deal; Immunovants setback in lupus (BioPharma Dive)
- Roivant reports top-line data from IMVT-1402 CLE trial (Clinical Trials Arena)
- Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal IMVT Stock Heads For Over 3-Month Lows (Stocktwits) -7.37%
- Roivants Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (InvestorsHub)
- Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint (InvestorsHub)
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus (GlobeNewswire)
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-11-09 | -0.470 | -0.737 | -0.470 | 0.00 | 0.00 | 14 |
| 2026Q1 | 2026-08-06 | -0.750 | -0.629 | -0.745 | 0.00 | 0.00 | 12 |
| 2025Q4 | 2026-05-20 | -0.730 | -0.592 | -0.726 | 0.00 | 0.00 | 16 |
| 2025Q3 | 2026-02-06 | -0.610 | -0.713 | -0.610 | 0.00 | 0.00 | 14 |
| 2025Q2 | 2025-11-10 | -0.730 | -0.714 | -0.729 | 0.00 | 0.00 | 15 |
| 2025Q1 | 2025-08-11 | -0.710 | -0.680 | -0.706 | 0.00 | 0.00 | 12 |
| 2024Q4 | 2025-05-29 | -0.640 | -0.713 | -0.638 | 0.00 | 0.00 | 12 |
| 2024Q3 | 2025-02-06 | -0.760 | -0.752 | -0.756 | 0.00 | 0.00 | 12 |
| 2024Q2 | 2024-11-07 | -0.740 | -0.600 | -0.745 | 0.00 | 0.00 | 15 |
| 2024Q1 | 2024-08-06 | -0.527 | -0.524 | -0.597 | 0.00 | 0.00 | 10 |
| 2023Q4 | 2024-05-29 | -0.520 | -0.430 | -0.518 | 0.00 | 0.00 | 14 |
| 2023Q3 | 2024-02-12 | -0.289 | -0.433 | -0.356 | 0.00 | 0.00 | 14 |
| 2023Q2 | 2023-11-09 | -0.450 | -0.453 | -0.447 | 0.00 | 0.00 | 14 |
| 2023Q1 | 2023-08-10 | -0.570 | -0.436 | -0.567 | 0.00 | 0.00 | 12 |
| 2022Q4 | 2023-05-22 | -0.460 | -0.423 | -0.459 | 0.00 | 0.00 | 13 |
| 2022Q3 | 2023-02-03 | -0.490 | -0.373 | -0.492 | 0.00 | 0.00 | 9 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | -1.540 | -1.094 | -1.537 | 0.00 | 0.00 |
| 2020FY | -1.220 | -1.302 | -1.224 | 0.00 | 0.00 |
| 2021FY | -1.430 | -1.410 | -1.429 | 0.00 | 0.00 |
| 2022FY | -1.710 | -1.603 | -1.714 | 0.00 | 0.00 |
| 2023FY | -1.880 | -1.789 | -1.878 | 0.00 | 0.00 |
| 2024FY | -2.730 | -2.807 | -2.730 | 0.00 | 0.00 |
| 2025FY | -2.770 | -2.612 | -2.770 | 0.00 | 0.00 |
| 2026FY | - | -2.593 | - | - | 0.00 |
| 2027FY | - | -2.653 | - | - | 46.85 |
| 2028FY | - | -1.695 | - | - | 393.03 |
| 2029FY | - | 0.299 | - | - | 920.55 |
| 2030FY | - | 2.757 | - | - | 1,681 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | S | 2026-11-09 | 7 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-11-08 | 7 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-08-21 | 8 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-08-07 | 7 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-08-06 | 6 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-07-31 | 6 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-07-21 | 5 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-06-29 | 6 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-05-24 | 5 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-05-21 | 6 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-05-20 | 5 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-02-13 | 7 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-02-06 | 6 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-19 | 3 | 0 | 0 | 0.00 | 0.00 | 0.00 |
Estimate history
| EPS, annual | 0 | -1.537 | -1.224 | -1.429 | -1.714 | -1.878 | -2.73 | -2.772 | -2.5513 |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -0.745 | -0.756 | -0.638 | -0.706 | -0.729 | -0.61 | -0.726 | -0.745 | -0.471 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Shares, annual | 14.375 | 54.655 | 97.971 | 116.483 | 130.33 | 145.583 | 170.112 | 203.94 | 206.786 |
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 146.565 | 147.204 | 170.112 | 171.069 | 174.533 | 203.317 | 203.94 | 206.265 | 206.786 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.38 | 0.41 | 0.38 | 0.23 | 1.32 | 1.23 | 1.00 | 0.02 | 0.00 |
| Gross Profit | -0.38 | -0.41 | -0.38 | -0.23 | -1.32 | -1.23 | -1.00 | -0.02 | 0.00 |
| Selling, General and Administrative Excl. Other | 538.02 | 532.49 | 437.77 | 269.98 | 206.95 | 154.80 | 107.12 | 59.66 | 0.00 |
| Research and Development | 468.85 | 456.66 | 360.92 | 212.93 | 160.26 | 101.81 | 68.60 | 47.93 | - |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -538.39 | -532.90 | -438.15 | -270.21 | -208.28 | -156.03 | -108.12 | -59.68 | -0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.62 | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 12.50 | 10.00 | 0.00 | 0.00 | 6.40 | - |
| Net Income Before Taxes | -510.25 | -505.39 | -412.95 | -258.77 | -210.95 | -156.81 | -107.79 | -66.29 | -0.00 |
| Income Taxes | -1.29 | 0.21 | 0.89 | 0.57 | 0.01 | -0.08 | -0.36 | 0.10 | 0.00 |
| Consolidated Net Income | -508.96 | -505.61 | -413.84 | -259.34 | -210.96 | -156.73 | -107.43 | -66.39 | -0.00 |
| Net Income From Continuing Operations | -508.96 | -505.61 | -413.84 | -259.34 | -210.96 | -156.73 | -107.43 | -66.39 | -0.00 |
| Net Income | -508.96 | -505.61 | -413.84 | -259.34 | -210.96 | -156.73 | -107.43 | -66.39 | -0.00 |
| EPS (Recurring) | -2.46 | -2.77 | -2.73 | -1.81 | -1.66 | -1.43 | -1.22 | -1.43 | -0.00 |
| EPS (Basic, Before Extraordinaries) | -2.55 | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 |
| EPS (Diluted) | -2.55 | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 |
| EBITDA | -538.02 | -532.49 | -437.77 | -269.98 | -206.95 | -154.80 | -107.12 | -59.66 | -0.00 |
| Non-Operating Income (Expense) | 28.14 | 27.51 | 25.20 | 23.94 | 7.33 | -0.78 | 0.33 | 0.41 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 42.29 | 43.36 | 39.08 | 32.40 | 25.25 | 26.18 | 13.61 | 4.96 | - |
| Shares Outstanding | 206.79 | 203.94 | 170.11 | 145.58 | 130.33 | 116.48 | 97.97 | 54.66 | 14.38 |
| Market Capitalization | 7,376.01 | 7,376.01 | 2,902.92 | 4,694.42 | 2,020.10 | 641.34 | 1,571.46 | 223.75 | 237.91 |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.10 |
| Gross Profit | -0.09 | -0.09 | -0.10 | -0.10 | -0.10 | -0.11 | -0.11 | -0.10 |
| Selling, General and Administrative Excl. Other | 104.07 | 160.23 | 159.46 | 114.26 | 131.66 | 127.12 | 113.72 | 114.20 |
| Research and Development | 85.01 | 142.63 | 142.29 | 98.92 | 114.25 | 101.20 | 93.65 | 94.52 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -104.16 | -160.32 | -159.55 | -114.36 | -131.76 | -127.22 | -113.83 | -114.30 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -97.25 | -153.22 | -150.70 | -109.08 | -125.91 | -119.70 | -105.87 | -110.97 |
| Income Taxes | 0.00 | 0.00 | -2.84 | 1.55 | 0.59 | 0.91 | 0.58 | 0.15 |
| Consolidated Net Income | -97.25 | -153.22 | -147.86 | -110.64 | -126.50 | -120.61 | -106.45 | -111.12 |
| Net Income From Continuing Operations | -97.25 | -153.22 | -147.86 | -110.64 | -126.50 | -120.61 | -106.45 | -111.12 |
| Net Income | -97.25 | -153.22 | -147.86 | -110.64 | -126.50 | -120.61 | -106.45 | -111.12 |
| EPS (Recurring) | -0.47 | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 |
| EPS (Basic, Before Extraordinaries) | -0.47 | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 |
| EPS (Diluted) | -0.47 | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 |
| EBITDA | -104.07 | -160.23 | -159.46 | -114.26 | -131.66 | -127.12 | -113.72 | -114.20 |
| Non-Operating Income (Expense) | 6.91 | 7.10 | 8.85 | 5.28 | 5.85 | 7.52 | 7.96 | 3.33 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 12.89 | 10.69 | 8.80 | 9.90 | 10.42 | 14.53 | 9.23 | 9.20 |
| Shares Outstanding | 206.79 | 206.26 | 203.94 | 203.32 | 174.53 | 171.07 | 170.11 | 147.20 |
| Market Capitalization | 7,376.01 | 7,910.56 | 5,055.73 | 5,121.55 | 2,809.99 | 2,734.77 | 2,902.92 | 3,635.86 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 902.11 | 713.97 | 635.37 | 376.53 | 493.82 | 400.15 | 100.57 | 0.33 |
| Short Term Receivables | 3.95 | 2.51 | 5.50 | 0.89 | 12.86 | 0.55 | 3.04 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 42.76 | 51.18 | 24.90 | 26.92 | 6.25 | 8.31 | 5.46 | 0.00 |
| Total Current Assets | 948.82 | 767.66 | 665.77 | 404.33 | 512.93 | 409.01 | 109.08 | 0.33 |
| Net Property, Plant & Equipment | 0.52 | 0.94 | 0.59 | 1.50 | 2.63 | 3.48 | 0.07 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | 0.55 | 1.10 | 0.35 | - | - | - | - | - |
| Other Assets | 7.68 | 7.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.08 |
| Total Assets | 957.57 | 777.32 | 666.71 | 405.84 | 515.56 | 412.49 | 109.39 | 0.41 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.07 | 0.10 | 0.14 | 1.52 | 1.32 | 1.18 | 3.19 | 0.30 |
| Accounts Payable | 7.54 | 17.66 | 7.16 | 1.35 | 18.63 | 2.43 | 1.19 | 0.00 |
| Other Current Liabilities | 96.81 | 51.02 | 41.31 | 40.42 | 24.57 | 15.16 | 10.94 | 0.08 |
| Total Current Liabilities | 104.42 | 68.78 | 48.61 | 43.30 | 44.52 | 18.77 | 15.32 | 0.38 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.05 | 1.22 | 2.24 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 0.55 | 1.10 | 0.35 | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 104.97 | 69.87 | 48.95 | 43.34 | 45.74 | 21.01 | 15.32 | 0.38 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 852.59 | 707.45 | 617.76 | 362.49 | 469.82 | 391.48 | 94.07 | 0.02 |
| Total Shareholders Equity | 852.59 | 707.45 | 617.76 | 362.49 | 469.82 | 391.48 | 94.07 | 0.02 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 852.59 | 707.45 | 617.76 | 362.49 | 469.82 | 391.48 | 94.07 | 0.02 |
| Total Liabilities & Stockholders Equity | 957.57 | 777.32 | 666.71 | 405.84 | 515.56 | 412.49 | 109.39 | 0.41 |
| Book Value Per Share | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 | 4.00 | 1.72 | 0.00 |
| Tangible Book Value Per Share | 4.18 | 4.16 | 4.24 | 2.78 | 4.03 | 4.00 | 1.72 | 0.00 |
| Full-Time Employees | 315 | 362 | 207 | 164 | 124 | 68 | 0 | - |
| Price to Book Ratio | 11.24 | 7.13 | 6.90 | 5.58 | 1.37 | 4.01 | 9.04 | 8.09 |
| Return on Assets | -58.29 | -57.32 | -48.36 | -45.79 | -33.78 | -41.17 | -120.93 | - |
| Return on Equity | -64.82 | -62.46 | -52.91 | -50.69 | -36.39 | -44.25 | -141.11 | - |
| Return on Invested Capital | -59.30 | -58.50 | -41.98 | -58.19 | -33.27 | -27.29 | -70.57 | -1.82 |
| Quick Ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 0.85 |
| Current Ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 0.85 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -508.96 | -505.61 | -413.84 | -259.34 | -210.96 | -156.73 | -107.43 | -66.39 | -0.00 |
| Depreciation | 0.38 | 0.41 | 0.38 | 0.23 | 1.32 | 1.23 | 1.00 | 0.02 | - |
| Other Funds (Non Cash) | 51.02 | 55.82 | 49.62 | 42.25 | 32.30 | 34.24 | 18.54 | 8.20 | 0.00 |
| Funds from Operations | -457.57 | -449.37 | -363.84 | -216.86 | -177.34 | -121.25 | -87.89 | -58.16 | -0.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 62.56 | 42.06 | -12.03 | 2.63 | -10.85 | 15.14 | 4.57 | 4.81 | 0.00 |
| Cash from Operating Activities | -395.00 | -407.31 | -375.87 | -214.23 | -188.19 | -106.11 | -83.33 | -53.36 | 0.00 |
| Capital Expenditures | -0.01 | -0.01 | -0.76 | -0.36 | -0.20 | -0.25 | -0.21 | -0.03 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.01 | -0.01 | -0.76 | -0.36 | -0.20 | -0.25 | -0.21 | -0.03 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 596.22 | 595.76 | 454.49 | 472.43 | 70.89 | 0.13 | 386.30 | -1.95 | 0.03 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 596.22 | 595.76 | 454.49 | 472.43 | 70.89 | 0.13 | 386.30 | -1.95 | 0.03 |
| Proceedsfrom Stock Options | 543.69 | 543.69 | 449.68 | 466.73 | 70.23 | 0.13 | 385.39 | -1.95 | 0.03 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.19 | 37.91 | 0.30 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00 | 0.00 | 111.02 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 596.22 | 595.76 | 454.49 | 472.43 | 70.89 | 200.13 | 383.11 | 146.97 | 0.33 |
| Exchange Rate Effect | -0.81 | -0.30 | 0.75 | 0.99 | 0.22 | -0.09 | - | - | - |
| Net Change in Cash | 200.40 | 188.14 | 78.61 | 258.83 | -117.28 | 93.67 | 299.57 | 93.59 | 0.33 |
| Free Cash Flow | -395.01 | -407.32 | -376.63 | -214.59 | -188.39 | -106.37 | -83.54 | -53.39 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 722.27 | 797.80 | 902.11 | 994.52 | 521.87 | 598.91 |
| Short Term Receivables | 0.14 | 0.70 | 3.95 | 1.64 | 1.97 | 1.94 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 37.63 | 52.68 | 42.76 | 46.77 | 49.71 | 50.91 |
| Total Current Assets | 760.05 | 851.18 | 948.82 | 1,042.94 | 573.55 | 651.76 |
| Net Property, Plant & Equipment | 0.26 | 0.35 | 0.52 | 0.53 | 0.63 | 0.74 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | 0.55 | - | - | - |
| Other Assets | 0.66 | 0.96 | 7.68 | 8.92 | 8.78 | 8.94 |
| Total Assets | 760.97 | 852.49 | 957.57 | 1,052.39 | 582.96 | 661.44 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 6.79 | 10.14 | 7.54 | 8.62 | 6.92 | 7.84 |
| Other Current Liabilities | 97.23 | 106.96 | 96.81 | 57.64 | 56.34 | 45.06 |
| Total Current Liabilities | 104.02 | 117.10 | 104.42 | 66.26 | 63.25 | 52.90 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | 0.55 | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 104.02 | 117.10 | 104.97 | 66.26 | 63.25 | 52.90 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 656.95 | 735.39 | 852.59 | 986.13 | 519.71 | 608.54 |
| Total Shareholders Equity | 656.95 | 735.39 | 852.59 | 986.13 | 519.71 | 608.54 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 656.95 | 735.39 | 852.59 | 986.13 | 519.71 | 608.54 |
| Total Liabilities & Stockholders Equity | 760.97 | 852.49 | 957.57 | 1,052.39 | 582.96 | 661.44 |
| Book Value Per Share | 3.18 | 3.57 | 4.18 | 4.85 | 2.98 | 3.56 |
| Tangible Book Value Per Share | 3.18 | 3.57 | 4.18 | 4.85 | 2.98 | 3.56 |
| Full-Time Employees | - | - | 315 | - | - | - |
| Price to Book Ratio | 11.24 | 9.22 | 5.12 | 8.54 | 4.53 | 3.85 |
| Return on Assets | -75.74 | -71.10 | -58.29 | -63.01 | -84.59 | -71.50 |
| Return on Equity | -86.51 | -80.10 | -64.82 | -69.35 | -95.93 | -77.58 |
| Return on Invested Capital | -14.80 | -20.84 | -17.34 | -11.22 | -24.34 | -19.82 |
| Quick Ratio | 7.31 | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 |
| Current Ratio | 7.31 | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -97.25 | -153.22 | -147.86 | -110.64 | -126.50 | -120.61 |
| Depreciation | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 |
| Other Funds (Non Cash) | 13.31 | 13.80 | 11.17 | 12.74 | 13.38 | 18.53 |
| Funds from Operations | -83.85 | -139.33 | -136.59 | -97.79 | -113.02 | -101.97 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.63 | 14.93 | 41.53 | 5.47 | 10.50 | -15.44 |
| Cash from Operating Activities | -83.22 | -124.41 | -95.06 | -92.33 | -102.52 | -117.41 |
| Capital Expenditures | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.88 | 20.10 | 3.64 | 564.60 | 24.59 | 2.92 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.88 | 20.10 | 3.64 | 564.60 | 24.59 | 2.92 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 544.28 | -0.59 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 7.88 | 20.10 | 3.64 | 564.60 | 24.59 | 2.92 |
| Exchange Rate Effect | -0.19 | -0.00 | -0.99 | 0.38 | 0.88 | -0.57 |
| Net Change in Cash | -75.52 | -104.31 | -92.42 | 472.65 | -77.04 | -115.06 |
| Free Cash Flow | -83.22 | -124.41 | -95.07 | -92.33 | -102.52 | -117.41 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 21.87% | 18.6M | 84.8M | 1.35M |
| 2026-10-15 | 21.54% | 18.3M | 84.8M | 1.29M |
| 2026-09-30 | 20.53% | 17.4M | 84.8M | 1.22M |
| 2026-09-15 | 20.34% | 17.3M | 84.8M | 1.26M |
| 2026-08-31 | 18.69% | 15.8M | 84.5M | 1.29M |
| 2026-08-14 | 20.11% | 17.0M | 84.5M | 1.70M |
| 2026-07-31 | 19.39% | 16.4M | 84.5M | 1.72M |
| 2026-07-15 | 21.71% | 17.8M | 81.8M | 1.89M |
| 2026-06-30 | 22.11% | 18.0M | 81.4M | 1.95M |
| 2026-06-15 | 23.79% | 19.3M | 81.3M | 1.84M |
| 2026-05-29 | 23.72% | 19.2M | 81.0M | 1.79M |
| 2026-05-15 | 25.16% | 20.4M | 81.0M | 1.36M |
| 2026-04-30 | 22.38% | 18.6M | 83.1M | 1.43M |
| 2026-04-15 | 23.49% | 19.5M | 83.0M | 1.34M |
| 2026-03-31 | 21.93% | 18.4M | 84.0M | 1.40M |
| 2026-03-13 | 19.71% | 16.6M | 84.0M | 1.46M |
| 2026-02-27 | 20.03% | 16.8M | 84.0M | 1.59M |
| 2026-02-13 | 20.17% | 17.0M | 84.0M | 1.63M |
| 2026-01-30 | 19.71% | 16.5M | 83.7M | 1.65M |
| 2026-01-15 | 20.24% | 16.9M | 83.7M | 1.80M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 19.00 | 15.60 | 18.60 | 0.00 | 3.730 | 0.00 | 0.00 | 0.929 | -0.152 | 0.008 |
| call | 20.00 | 14.60 | 18.10 | 0.00 | 4.022 | 0.00 | 0.00 | 0.924 | -0.150 | 0.008 |
| call | 21.00 | 13.60 | 17.20 | 0.00 | 3.856 | 0.00 | 0.00 | 0.919 | -0.148 | 0.009 |
| call | 22.00 | 12.60 | 16.00 | 0.00 | 3.436 | 0.00 | 0.00 | 0.913 | -0.145 | 0.009 |
| call | 23.00 | 11.60 | 15.20 | 0.00 | 3.382 | 0.00 | 0.00 | 0.907 | -0.143 | 0.010 |
| call | 24.00 | 10.60 | 13.80 | 0.00 | 2.837 | 0.00 | 0.00 | 0.900 | -0.140 | 0.010 |
| call | 25.00 | 9.60 | 13.20 | 0.00 | 2.945 | 0.00 | 0.00 | 0.892 | -0.137 | 0.011 |
| call | 26.00 | 8.60 | 11.50 | 3.70 | 2.192 | 5.00 | 0.00 | 0.884 | -0.133 | 0.011 |
| call | 27.00 | 7.60 | 10.80 | 0.00 | 2.250 | 0.00 | 0.00 | 0.875 | -0.130 | 0.012 |
| call | 28.00 | 6.60 | 9.20 | 3.22 | 1.624 | 58.00 | 0.00 | 0.864 | -0.125 | 0.013 |
| call | 29.00 | 5.60 | 9.00 | 1.85 | 2.036 | 30.00 | 0.00 | 0.833 | -0.145 | 0.014 |
| call | 30.00 | 4.60 | 7.90 | 1.50 | 1.781 | 144 | 0.00 | 0.818 | -0.139 | 0.015 |
| call | 31.00 | 3.90 | 6.20 | 4.95 | 1.149 | 65.00 | 0.00 | 0.800 | -0.132 | 0.016 |
| call | 32.00 | 2.75 | 6.10 | 3.96 | 1.534 | 13.00 | 0.00 | 0.778 | -0.124 | 0.017 |
| call | 33.00 | 2.10 | 5.30 | 0.70 | 1.462 | 23.00 | 0.00 | 0.746 | -0.119 | 0.018 |
| call | 34.00 | 1.50 | 3.80 | 0.95 | 1.036 | 29.00 | 0.00 | 0.685 | -0.136 | 0.020 |
| call | 35.00 | 1.00 | 2.80 | 0.55 | 0.838 | 146 | 0.00 | 0.644 | -0.118 | 0.021 |
| call | 36.00 | 0.10 | 2.05 | 0.49 | 0.845 | 7.00 | 0.00 | 0.573 | -0.155 | 0.023 |
| call | 37.00 | 0.00 | 1.50 | 0.90 | 0.838 | 4.00 | 0.00 | 0.515 | -0.152 | 0.023 |
| call | 38.00 | 0.00 | 1.15 | 0.20 | 1.016 | 22.00 | 0.00 | 0.458 | -0.152 | 0.023 |
| call | 39.00 | 0.00 | 0.90 | 0.95 | 1.173 | 66.00 | 0.00 | 0.410 | -0.154 | 0.022 |
| call | 40.00 | 0.00 | 0.70 | 0.15 | 1.034 | 64.00 | 0.00 | 0.327 | -0.123 | 0.021 |
| call | 41.00 | 0.00 | 1.15 | 0.00 | 1.157 | 0.00 | 0.00 | 0.298 | -0.129 | 0.020 |
| call | 42.00 | 0.00 | 1.90 | 0.00 | 1.277 | 0.00 | 0.00 | 0.279 | -0.137 | 0.019 |
| call | 43.00 | 0.00 | 1.60 | 0.00 | 1.385 | 0.00 | 0.00 | 0.264 | -0.145 | 0.019 |
| call | 44.00 | 0.00 | 1.40 | 0.00 | 1.497 | 0.00 | 0.00 | 0.251 | -0.152 | 0.018 |
| call | 45.00 | 0.00 | 1.00 | 1.45 | 1.499 | 2.00 | 0.00 | 0.224 | -0.143 | 0.017 |
| call | 50.00 | 0.00 | 1.25 | 0.90 | 1.919 | 2.00 | 0.00 | 0.189 | -0.165 | 0.016 |
| call | 55.00 | 0.00 | 1.55 | 0.55 | 2.266 | 2.00 | 0.00 | 0.168 | -0.181 | 0.014 |
| put | 19.00 | 0.00 | 0.95 | 0.00 | 3.481 | 0.00 | 0.00 | -0.071 | -0.150 | 0.008 |
| put | 20.00 | 0.00 | 0.95 | 0.25 | 3.219 | 26.00 | 0.00 | -0.077 | -0.146 | 0.008 |
| put | 21.00 | 0.00 | 1.15 | 0.30 | 3.044 | 15.00 | 0.00 | -0.081 | -0.145 | 0.009 |
| put | 22.00 | 0.00 | 1.20 | 0.60 | 2.836 | 9.00 | 0.00 | -0.087 | -0.142 | 0.009 |
| put | 23.00 | 0.00 | 1.15 | 0.35 | 2.653 | 3.00 | 0.00 | -0.093 | -0.140 | 0.010 |
| put | 24.00 | 0.00 | 1.20 | 0.40 | 2.414 | 29.00 | 0.00 | -0.103 | -0.135 | 0.010 |
| put | 25.00 | 0.00 | 1.15 | 1.20 | 2.233 | 49.00 | 0.00 | -0.111 | -0.132 | 0.011 |
| put | 26.00 | 0.00 | 1.20 | 1.60 | 2.110 | 2.00 | 0.00 | -0.116 | -0.130 | 0.011 |
| put | 27.00 | 0.00 | 1.15 | 1.11 | 1.926 | 7.00 | 0.00 | -0.126 | -0.126 | 0.012 |
| put | 28.00 | 0.00 | 0.80 | 1.02 | 1.714 | 29.00 | 0.00 | -0.142 | -0.120 | 0.013 |
| put | 29.00 | 0.00 | 1.30 | 1.50 | 1.788 | 22.00 | 0.00 | -0.167 | -0.141 | 0.014 |
| put | 30.00 | 0.00 | 1.60 | 0.41 | 1.571 | 12.00 | 0.00 | -0.189 | -0.132 | 0.015 |
| put | 31.00 | 0.00 | 1.80 | 0.40 | 1.451 | 50.00 | 0.00 | -0.201 | -0.128 | 0.016 |
| put | 32.00 | 0.00 | 1.05 | 0.55 | 1.288 | 33.00 | 0.00 | -0.222 | -0.121 | 0.017 |
| put | 33.00 | 0.00 | 1.10 | 0.95 | 1.146 | 0.00 | 0.00 | -0.253 | -0.116 | 0.018 |
| put | 34.00 | 0.00 | 0.75 | 1.57 | 1.224 | 9.00 | 0.00 | -0.313 | -0.133 | 0.020 |
| put | 35.00 | 0.00 | 1.00 | 1.80 | 1.032 | 30.00 | 0.00 | -0.356 | -0.114 | 0.021 |
| put | 36.00 | 0.05 | 1.35 | 0.00 | 1.492 | 0.00 | 0.00 | -0.427 | -0.151 | 0.023 |
| put | 37.00 | 1.10 | 1.85 | 4.80 | 1.607 | 12.00 | 0.00 | -0.485 | -0.148 | 0.023 |
| put | 38.00 | 0.80 | 4.40 | 9.15 | 1.606 | 4.00 | 0.00 | -0.542 | -0.149 | 0.023 |
| put | 39.00 | 1.35 | 4.90 | 0.00 | 1.506 | 0.00 | 0.00 | -0.591 | -0.149 | 0.022 |
| put | 40.00 | 2.20 | 5.90 | 10.95 | 1.654 | 1.00 | 0.00 | -0.674 | -0.118 | 0.021 |
| put | 41.00 | 3.20 | 6.80 | 0.00 | 1.754 | 0.00 | 0.00 | -0.702 | -0.124 | 0.020 |
| put | 42.00 | 4.10 | 7.70 | 0.00 | 1.873 | 0.00 | 0.00 | -0.721 | -0.133 | 0.019 |
| put | 43.00 | 5.10 | 8.70 | 0.00 | 1.956 | 0.00 | 0.00 | -0.736 | -0.140 | 0.019 |
| put | 44.00 | 6.00 | 9.70 | 0.00 | 2.070 | 0.00 | 0.00 | -0.748 | -0.146 | 0.018 |
| put | 45.00 | 7.00 | 10.70 | 0.00 | 2.177 | 0.00 | 0.00 | -0.776 | -0.138 | 0.017 |
| put | 50.00 | 11.60 | 15.60 | 0.00 | 2.600 | 0.00 | 0.00 | -0.811 | -0.160 | 0.016 |
| put | 55.00 | 16.60 | 20.60 | 0.00 | 2.981 | 0.00 | 0.00 | -0.832 | -0.175 | 0.014 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-09 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | SEC | |
| 2026-11-09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-10-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-28 | SEC |
| 2026-10-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-21 | SEC |
| 2026-10-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-07 | SEC |
| 2026-10-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-07 | SEC |
| 2026-10-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-07 | SEC |
| 2026-10-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-09-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-23 | SEC |
| 2026-09-03 | 8-K | Current report | 2026-09-02 | SEC |
| 2026-08-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-28 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-20 | SEC |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-23 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-24 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-23 | SEC |
| 2026-07-22 | ARS | Annual report to security holders. | 2026-03-31 | SEC |
| 2026-07-22 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-07-22 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-09-02 | SEC |
| 2026-07-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-08 | SEC |
| 2026-07-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-08 | SEC |
| 2026-07-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-08 | SEC |
| 2026-07-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-01 | SEC |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 619.47K | 6 |
| 2026-09 | 0 | 0 | 103.48K | 1 |
| 2026-08 | 0 | 0 | 199.86K | 2 |
| 2026-07 | 0 | 0 | 818.39K | 7 |
| 2026-06 | 0 | 0 | 3.48M | 7 |
| 2026-05 | 0 | 0 | 7.80M | 4 |
| 2026-04 | 0 | 0 | 1.78M | 6 |
| 2026-03 | 0 | 0 | 71.84K | 1 |
| 2026-02 | 0 | 0 | 90.18K | 1 |
| 2026-01 | 0 | 0 | 83.38K | 2 |
| 2025-12 | 350.00M | 1 | 1.16M | 3 |
| 2025-11 | 0 | 0 | 298.24K | 1 |
Institutional holders
| Manager | % owned |
|---|---|
| FMR LLC | 7.60% |
| Deep Track Capital, LP | 4.55% |
| BlackRock, Inc. | 3.50% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.83% |
| BAKER BROS. ADVISORS LP | 2.65% |
| STATE STREET CORP | 2.25% |
| Two Seas Capital LP | 2.23% |
| MORGAN STANLEY | 2.21% |
| TCG Crossover Management, LLC | 2.17% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.90% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Growth Company Fund | 2.47% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.27% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1.25% |
| iShares Russell 2000 ETF | 1.07% |
| VANGUARD SMALL-CAP INDEX FUND | 0.92% |
| Fidelity Growth Company K6 Fund | 0.68% |
| Fidelity Series Growth Company Fund | 0.53% |
| VANGUARD SMALL-CAP GROWTH INDEX FUND | 0.53% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.48% |
| PGIM Jennison Small Company Fund | 0.48% |
OakChart. IMVT. Cached 15 minutes.